Theodore Karrison

Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.

Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients.

Data management and statistical methods used in the analysis of balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and therapy-related acute leukemia: report from an international workshop.

Evaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs' test with ETCOc for detecting significant jaundice.

Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates.

Troxacitabine in patients with refractory leukemia.

Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.

Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.

Predictors of emergency medical services utilization by elders.

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

The aspect ratio (dome/neck) of ruptured and unruptured aneurysms.

A group sequential, response-adaptive design for randomized clinical trials.

Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study.

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage.

A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.

Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors.

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.

Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial.

Fetal loss associated with excess thyroid hormone exposure.

The human BCL6 transgene promotes the development of lymphomas in the mouse.

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.

Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.

Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.

Studies in hemolysis in glucose-6-phosphate dehydrogenase-deficient African American neonates.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies.

Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70.

Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.

A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.

Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus.

Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial.

Critical evaluation of diagnostic aids for the detection of oral cancer.

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Reproducibility and sources of variability in radiographic texture analysis of densitometric calcaneal images.

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

Modeling major lung resection outcomes using classification trees and multiple imputation techniques.

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.

A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.

Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.

What does it cost physician practices to interact with health insurance plans?

Frequency of failure to inform patients of clinically significant outpatient test results.

Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

Common fragile sites are characterized by histone hypoacetylation.

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Impaired replication dynamics at the FRA3B common fragile site.

Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development.

CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Outcomes in black patients with early breast cancer treated with breast conservation therapy.

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

A phase I study of continuous infusion cilengitide in patients with solid tumors.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.

Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-Small-Cell Lung Cancer, A Phase II Trial.

MET and phosphorylated MET as potential biomarkers in lung cancer.

Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

Resampling phase III data to assess phase II trial designs and endpoints.